Virtual Library
Start Your Search
L.X. Rodriguez
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-042 - Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non-Small Cell Lung Cancer (NSCLC) in a University Hospital in Latin America (ID 1457)
09:30 - 09:30 | Author(s): L.X. Rodriguez
- Abstract
Background:
The presence of activating gene mutations in the epidermal growth factor receptor of non-small cell lung cancer patients is predictive. It improved progression-free survival and improved response rate when treated with small molecule tyrosine kinase inhibitors. Together, exon 19 deletion and exon 21 L858R gene substitution are present in about 10% of Caucasian patients and in 20–40% of Asian patients. Moreover, guidelines now suggest EGFR gene mutation testing should be conducted in all patients with lung adenocarcinoma or mixed lung cancers with an adenocarcinoma component, regardless of characteristics such as smoking status, gender or race. The success of targeted therapies in non-small cell lung cancer patients has changed the treatment paradigm in metastatic non-small cell lung cancer. We describe the frequency of mutations in exons 19 and 21 of the EGFR gene in (NSCLC) in our hospital
Methods:
Between June 2013 and March 2015, 73 samples of lung tissue of patients with NSCLC were obtained in Fundacion Valle del Lili Cali-Colombia. Microdissection cuts on paraffin-embedded lung tissue was performed with the objective of increasing the amount of tumor DNA. DNA was extracted with DNA FFPE Tissue Kit QIAamo Kit (Qiagen), then amplified with PCR and exons 19 and 20 of EGFR mutations studied for amplification. Visualization was performed using microfluidic electrophoresis in the Agilent Bioanalyzer.
Results:
We analyzed tumor samples from 73 patients with NSCLC by PCR and RFLP. Good quantity and quality of DNA in 96% (70) cases was obtained. The average age was 65.6 years ± SD, 69% (48) women and 31% (22) men. EGFR mutations were observed in 21% (15) of the samples with 80% (12) in females. 47% of mutations were in exon 19 and 53% in exon 21. 80% of cases with mutations were adenocarcinomas. 53% of patients with mutations were in stage IV disease and 33% of patients received the tyrosine kinase inhibitor.
Conclusion:
In patients who are properly selected for EGFR-positive gene mutations, EGFR-TKIs have been shown to improve symptom control and quality of life, especially in frail elderly patients who desire to avoid the systemic side effects of cytotoxic chemotherapy while achieving a certain level of clinical efficacy. As more clinical trials for novel third-generation EGFR TKIs and other alternative therapies mature, better understanding may be gained through the use of these agents in improving treatment efficacy in adenocarcinoma or even squamous cell histology of metastatic NSCLC. Figure 1
